Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Matthew Langer Meyerson, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Matthew Meyerson and Laura MacConaill.
Connection Strength

2.221
  1. Adding pathogens by genomic subtraction. Nat Genet. 2008 Apr; 40(4):380-2.
    View in: PubMed
    Score: 0.403
  2. Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583. Mol Cancer Res. 2006 Oct; 4(10):793-801.
    View in: PubMed
    Score: 0.363
  3. Unique, dual-indexed sequencing adapters with UMIs effectively eliminate index cross-talk and significantly improve sensitivity of massively parallel sequencing. BMC Genomics. 2018 01 08; 19(1):30.
    View in: PubMed
    Score: 0.198
  4. Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations. JAMA Oncol. 2017 Jun 01; 3(6):801-809.
    View in: PubMed
    Score: 0.190
  5. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062.
    View in: PubMed
    Score: 0.183
  6. BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 2015 Feb 18; 43(3):e19.
    View in: PubMed
    Score: 0.160
  7. Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One. 2013; 8(9):e74950.
    View in: PubMed
    Score: 0.147
  8. Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov. 2011 Sep; 1(4):297-311.
    View in: PubMed
    Score: 0.128
  9. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009 Nov 18; 4(11):e7887.
    View in: PubMed
    Score: 0.113
  10. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clin Cancer Res. 2021 Mar 15; 27(6):1695-1705.
    View in: PubMed
    Score: 0.061
  11. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2019 01; 565(7738):E5-E6.
    View in: PubMed
    Score: 0.053
  12. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. Int J Cancer. 2015 Aug 15; 137(4):776-83.
    View in: PubMed
    Score: 0.041
  13. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012 Mar 28; 483(7391):603-7.
    View in: PubMed
    Score: 0.033
  14. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012 Jan; 2(1):82-93.
    View in: PubMed
    Score: 0.032
  15. Tumor genomic profiling of FFPE samples by massively parallel sequencing. J Clin Oncol. 2011 May 20; 29(15_suppl):10502.
    View in: PubMed
    Score: 0.031
  16. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011 Aug 01; 29(22):3085-96.
    View in: PubMed
    Score: 0.031
  17. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010 Sep 16; 116(11):1919-23.
    View in: PubMed
    Score: 0.029
  18. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.